|
Indivior PLC - Richmond, Virginia-based pharmaceutical firm - Enters into a settlement agreement with Indian pharmaceutical company Dr Reddy's Laboratories Ltd and its subsidiaries together with Aquestive Therapeutics Inc. Explains that the settlement is for a patent infringement case regarding DRL's generic buprenorphine and naloxone sublingual film that is equivalent to its Suboxone sublingual film.
Says that the settlement resolves all claims between the parties. Says the amount it had to pay to DRL following the settlement is consistent with its previously disclosed reserve amount.
In November 2018, DRL filed two petitions against Indivior's Suboxone patent so it could launch a cheaper generic version of the drug.
In June 2020, the Patent Trial & Appeal Board of the US Patent & Trademark Office ruled that some parts of Indivior's patent for Suboxone are ‘unpatentable’.
Current stock price: 310.13 pence, up 2.3% on Friday
12-month change: more than doubled from 144.70
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
